Coronavirus / COVID

Peter Hotez, MD, PhD, discusses the need to take a grounded approach when discussing plans for the introduction of vaccine immunity against COVID-19.

This finding suggests large disparities in kids and echoes adult population positive rates.

BARDA is committing over $1 billion for the agreement, which is dependent on approval or emergency use authorization by the US FDA.

The Novavax NVX-CoV2373 vaccine candidate is shown to be well-tolerated and elicited antibody response.

Disease severity was higher among people of color hospitalized with COVID-19, according to a review of chest X-rays.

Two studies will investigate monoclonal antibody-based treatments in both patients with mild disease and those who are hospitalized.

An understanding of what one country saw earlier this year and the prospect of what other countries can do for future openings.

Dr. Patrick Soon-Shiong, CEO of ImmunityBio, initiates a conversation on the nature of the SARS-CoV-2 cytokine storm.

Adam Brufsky, MD, explains the insights years of research into SARS-CoV-1 may hold for SARS-CoV-2.

As the debate on hydroxychloroquine rages on, the FDA and a new advocacy group have sparred about the appropriateness of physicians prescribing the drug for COVID-19.

A New York City cardiologist talks about the presentation of patients with severe COVID-19 who experienced this condition.

After review of 2 randomized trials, a panel of health care providers and patients see limited benefit for the medication.

The trial will assess a monoclonal antibody based investigational treatment that may prevent COVID-19.

The VIP antiviral therapy shows capability in reducing COVID-19 inflammatory biomarkers, as well as respiratory failure risks.

Collodial stability measures may predict whether a potential antibody-based treatment will work early on in the drug development process.

Medha Munshi, MD, discusses the specific challenges of the quarantine and how she was able to help her patients with diabetes comply with their care.

New findings show "structural inequities" among the US and UK frontline responders first infected months ago.

Dr. Anthony Fauci, CDC's Dr. Robert Redfield, & HHS' Admiral Brett Giroir spoke at a congressional hearing on coordinating the future of the national coronavirus response.

GSK, Sanofi were selected by US Operation Warp Speed to provide a large supply.

A look at the history of vaccines, our society's current standing in public health and vaccine preparedness, and what may come in the near future.

What role does new research play in combating public vaccination concerns?

Peter Hotez, MD, PhD, recently authored a paper proposing a federally directed but state-adaptive reopening that aims for acceptable national suppression by October 1.

IDSA, HIVMA request they be included in ongoing COVID-19 clinical trials.

A discussion on the process by which the FDA regulates vaccine candidates at a time when COVID-19 candidates are progressing.

Here is a compilation of the COVID-19 vaccine candidates that have achieved FDA Emergency Use Authorization, other approvals, and are in phases 1-3.